Workup of LADA
Test for islet autoantibodies (GAD, IA-2, and ZnT8) in any adult with newly diagnosed diabetes who has clinical features atypical for type 2 diabetes, and measure C-peptide if the patient is already on insulin to confirm beta-cell function status.
When to Suspect LADA and Initiate Testing
The 2025 ADA Standards of Care 1 classify LADA as a form of type 1 diabetes and provide a clear algorithmic approach for workup. You should suspect LADA and test for autoantibodies when adults present with:
- Age <35 years at diagnosis (though LADA can occur at any adult age)
- Lean body habitus (BMI <25 kg/m²) 2, 3, 4
- Absence of metabolic syndrome features (no insulin resistance, favorable lipid profile with high HDL and low triglycerides) 5
- Progressive hyperglycemia despite oral agents 2, 3
- Symptomatic hyperglycemia (polyuria, polydipsia, weight loss) 5
- Personal or family history of autoimmune disease 3
- HbA1c <7.5% at diagnosis 1
Specific Laboratory Tests
Primary Autoantibody Testing
Glutamic acid decarboxylase (GAD) antibodies should be measured first 1. GAD is the most frequently positive autoantibody in LADA 6, 3. If GAD is negative but clinical suspicion remains high, proceed to:
- IA-2 (islet tyrosine phosphatase 2) antibodies
- ZnT8 (zinc transporter 8) antibodies 1
A positive result on any of these confirms autoimmune diabetes. However, a critical caveat: testing autoantibodies in patients without clinical features suggestive of autoimmune diabetes will yield false positives due to low disease prevalence in that population 7. Single positive antibodies in clinically typical type 2 diabetes patients likely represent false positives 7.
C-Peptide Measurement
C-peptide testing is only indicated if the patient is already on insulin 1. The ADA guideline specifies:
- Measure random C-peptide (with concurrent glucose) within 5 hours of eating
- <200 pmol/L (<0.6 ng/mL): Confirms type 1 diabetes/LADA with significant beta-cell loss
- 200-600 pmol/L (0.6-1.8 ng/mL): Indeterminate, suggests partial beta-cell function
- >600 pmol/L (>1.8 ng/mL): Suggests type 2 diabetes
Important pitfall: A "low-normal" C-peptide (e.g., 1.3 ng/mL as in 2) should prompt autoantibody testing, as this represents borderline beta-cell function in the context of hyperglycemia 2. Don't be falsely reassured by technically normal values.
Algorithmic Approach
Following the ADA flowchart 1:
- Adult with suspected autoimmune diabetes → Test islet autoantibodies
- If autoantibody positive → Diagnosis is type 1 diabetes/LADA
- If autoantibody negative AND age <35 years → Still likely type 1 diabetes (5-10% are antibody-negative)
- If autoantibody negative AND age >35 years → Consider C-peptide testing if on insulin for >3 years' duration
Clinical Context Matters
The prevalence of LADA among adults diagnosed with "type 2 diabetes" ranges from 6-50% depending on the population studied 6, with recent primary care data showing approximately 7.5% prevalence 5. Most LADA patients require insulin within 3 years 6, making early identification crucial to avoid treatment failure and complications.
Patients with LADA demonstrate progressive beta-cell decline similar to classic type 1 diabetes 6. The intermediate presentation—initial insulin independence but with autoimmune markers—explains why misdiagnosis as type 2 diabetes is common 8, 3, 4.
What NOT to Do
- Don't rely on age alone: LADA occurs across all adult ages 8, 5
- Don't test autoantibodies indiscriminately: Only test when clinical features suggest autoimmune diabetes to avoid false positives 7
- Don't dismiss low-normal C-peptide: Values in the lower normal range warrant autoantibody testing 2
- Don't delay testing in patients with autoimmune clustering: Concurrent autoimmune conditions (thyroiditis, Sjögren's) increase LADA likelihood 3